Retour
Également cotée sous
AMBBY
OTC
Fourchette du Jour
13,00 €
13,65 €
Fourchette 52 Semaines
12,75 €
19,35 €
Volume
600
Moyenne 50J / 200J
13,40 €
/
14,32 €
Clôture Précédente
13,65 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 6,0 | 0,3 |
| P/B | 0,6 | 2,9 |
| ROE % | 10,5 | 3,7 |
| Net Margin % | 10,1 | 3,8 |
| Rev Growth 5Y % | 10,7 | 10,0 |
| D/E | 0,1 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
6,23 €
6,17 € – 6,29 €
|
10 B | 1 |
| FY2029 |
5,08 €
5,04 € – 5,13 €
|
9 B | 1 |
| FY2028 |
4,28 €
4,24 € – 4,33 €
|
8,1 B | 1 |
Points Clés
Revenue grew 10,70% annually over 5 years — strong growth
Earnings grew 158,66% over the past year
ROE of 10,46% — decent returns on equity
Debt/Equity of 0,09 — conservative balance sheet
Generating 672,72M in free cash flow
P/E of 6,02 — trading at a low valuation
Croissance
Revenue Growth (5Y)
10,70%
Revenue (1Y)11,78%
Earnings (1Y)158,66%
FCF Growth (3Y)87,18%
Qualité
Return on Equity
10,46%
ROIC8,93%
Net Margin10,09%
Op. Margin12,99%
Sécurité
Debt / Equity
0,09
Current Ratio2,72
Interest Coverage26,13
Valorisation
P/E Ratio
6,02
P/B Ratio0,61
EV/EBITDA4,27
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11,78% | Revenue Growth (3Y) | 12,34% |
| Earnings Growth (1Y) | 158,66% | Earnings Growth (3Y) | 90,21% |
| Revenue Growth (5Y) | 10,70% | Earnings Growth (5Y) | 25,25% |
| Profitability | |||
| Revenue (TTM) | 6,03B | Net Income (TTM) | 607,84M |
| ROE | 10,46% | ROA | 7,94% |
| Gross Margin | 55,97% | Operating Margin | 12,99% |
| Net Margin | 10,09% | Free Cash Flow (TTM) | 672,72M |
| ROIC | 8,93% | FCF Growth (3Y) | 87,18% |
| Safety | |||
| Debt / Equity | 0,09 | Current Ratio | 2,72 |
| Interest Coverage | 26,13 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 6,02 | P/B Ratio | 0,61 |
| P/S Ratio | 0,61 | PEG Ratio | 0,27 |
| EV/EBITDA | 4,27 | Dividend Yield | 0,00% |
| Market Cap | 3,66B | Enterprise Value | 3,34B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6,03B | 5,39B | 4,78B | 4,44B | 4,01B |
| Net Income | 607,84M | 235,00M | 168,00M | 93,00M | 247,00M |
| EPS (Diluted) | 2,28 | 0,88 | 0,64 | 0,37 | 0,98 |
| Gross Profit | 3,37B | 3,20B | 2,71B | 2,55B | 2,50B |
| Operating Income | 782,51M | 645,00M | 302,00M | -26,00M | 340,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7,66B | 7,15B | 6,86B | 7,22B | 5,74B |
| Total Liabilities | 1,64B | 1,56B | 1,47B | 2,95B | 1,79B |
| Shareholders' Equity | 6,02B | 5,59B | 5,39B | 4,26B | 3,95B |
| Total Debt | 545,96M | 558,00M | 584,00M | 1,85B | 823,00M |
| Cash & Equivalents | 864,35M | 615,00M | 157,00M | 187,00M | 64,00M |
| Current Assets | 3,15B | 2,64B | 2,01B | 2,30B | 1,61B |
| Current Liabilities | 1,16B | 1,06B | 942,00M | 1,16B | 980,00M |
Scores de Stratégies
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Activité Récente
Entré
Cash Flow Compounder
Mar 24, 2026
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026